|
Elucidation of cancer pathways and druggable targets using mouse models.
|
5U01CA084294-13
|
$873,915
|
$87,392
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-03
|
$1,902,504
|
$1,902,504
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$822,907
|
$123,436
|
Aladjem, Mirit
|
CCR (NCI)
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-02
|
$413,032
|
$413,032
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
THE THERAPY OF AML
|
5P01CA055164-19
|
$2,401,083
|
$312,141
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-27
|
$615,630
|
$615,630
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB
|
5R01CA073756-12
|
$252,369
|
$252,369
|
BALDWIN, ALBERT
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-02
|
$2,904,341
|
$2,526,777
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Molecular Control of EGF Receptor Down-Regulation
|
5R01CA099163-11
|
$328,717
|
$108,477
|
Band, Hamid
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Malignant melanoma: Regulation by AP-2 and PAR-1
|
5R01CA076098-12
|
$262,932
|
$65,733
|
BARELI, MENASHE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Postdoctoral Research Training in Biotherapy of Cancer
|
2T32CA113263-06A1
|
$174,265
|
$34,853
|
BARTLETT, DAVID
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-12
|
$2,117,925
|
$254,151
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
7R01CA142873-02
|
$49,462
|
$16,322
|
BASTIAN, BORIS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
BRAIN TUMOR SPORE GRANT
|
5P50CA097257-10
|
$2,140,227
|
$107,011
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Mechanism of p53 Silencing By Adenovirus E1B 55K Protein
|
5R01CA064799-15
|
$216,419
|
$216,419
|
BERK, ARNOLD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Non-viral gene delivery with DNA nanostructures
|
1R21CA158977-01
|
$172,460
|
$172,460
|
Bermudez, Harry
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-13
|
$377,387
|
$75,477
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-33
|
$177,227
|
$35,445
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
JHU ICMIC Program
|
2P50CA103175-06A2
|
$1,619,134
|
$323,827
|
BHUJWALLA, ZAVER
|
JOHNS HOPKINS UNIVERSITY
|
|
Image-guided Prodrug and siRNA Targeting of Cancer
|
5R01CA138515-03
|
$330,091
|
$330,091
|
Bhujwalla, Zaver
|
JOHNS HOPKINS UNIVERSITY
|
|
Re-activation of maspin tumor suppressor gene by designed transcription factors
|
5R01CA125273-05
|
$269,078
|
$67,270
|
BLANCAFORT, PILAR
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-10
|
$306,692
|
$30,669
|
Bland, Kirby
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Mechanisms of Viral Fusion and Inactivation
|
ZIA BC 008303
|
$327,538
|
$32,753
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Lipid-based Nanocapsules and Triggered Chemotherapy
|
ZIA BC 010652
|
$491,306
|
$147,391
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-08
|
$278,762
|
$69,691
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-02
|
$310,970
|
$102,620
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Tumor exosomes as agents of genetic change
|
5R01CA141150-03
|
$285,005
|
$285,005
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Regulation of the Sodium/Iodide Symporter in Breast
|
5R01CA089364-09
|
$208,996
|
$20,900
|
BRENT, GREGORY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-03
|
$381,617
|
$381,617
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Invasive Behavior of Tumor Cells Producing Collagenase-1
|
5R01CA077267-10
|
$235,742
|
$47,148
|
BRINCKERHOFF, CONSTANCE
|
DARTMOUTH COLLEGE
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
5R01CA095731-09
|
$266,570
|
$133,285
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Gene repression by HSF1 during hyperthermia and other stresses.
|
5R01CA077465-08
|
$220,209
|
$22,021
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer
|
5K08CA142904-02
|
$173,448
|
$173,448
|
Camp, Ernest
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
5R01CA151391-02
|
$346,193
|
$173,097
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INSTITUTE
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-03
|
$661,137
|
$165,284
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
Aspects of MUC13 Mucin in Cancer
|
5R01CA142736-02
|
$306,622
|
$153,311
|
Chauhan, Subhash
|
SANFORD RESEARCH/USD
|
|
Overcoming Immune Suppression to Enhance Tumor Vaccine Efficacy
|
5R01CA090427-08
|
$316,496
|
$316,496
|
Chen, Si-Yi
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Targeted delivery of IKKalpha siRNA to prostate cancer cells
|
5R21CA143683-02
|
$191,473
|
$191,473
|
Cheng, Kun
|
UNIVERSITY OF MISSOURI KANSAS CITY
|
|
Genetic Therapy for Fanconi Anemia
|
1R01CA155294-01
|
$319,550
|
$319,550
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-05
|
$270,405
|
$270,405
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
MOTILITY AND INVASION
|
3P01CA100324-09S1
|
$72,007
|
$7,201
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
MOTILITY AND INVASION
|
5P01CA100324-09
|
$2,023,001
|
$202,300
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Enhancing the efficacy of CD19-specific cord blood-derived T Cells
|
5R01CA120956-05
|
$283,822
|
$283,822
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adoptive immunotherapy after umbilical cord blood transplant
|
5R01CA124782-05
|
$283,822
|
$283,822
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
|
5R01CA141303-02
|
$318,015
|
$318,015
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
5R33CA116127-04
|
$459,850
|
$459,850
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,173,211
|
$293,302
|
Court, Donald
|
CCR (NCI)
|
|
FHIT Gene Therapy in Cancer Prevention and Treatment
|
5R01CA115965-05
|
$221,160
|
$221,160
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
Role of miR155 in Leukemogenesis
|
5R01CA124541-04
|
$301,992
|
$150,996
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
1R01CA154697-01A1
|
$517,924
|
$517,924
|
Curiel, David
|
WASHINGTON UNIVERSITY
|
Total relevant funding to Gene Therapy for this search: $67,165,721
|